NCT03837977View on ClinicalTrials.gov

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

November 26, 2024

Study Completion Date

November 26, 2024

Conditions

OncologyNeuroendocrine Carcinoma

Interventions

DRUG

Liposomal Irinotecan

Arm I

DRUG

Fluorouracil

Arm I

DRUG

Folinic Acid

Arm I

DRUG

Docetaxel

Arm II

Trial Locations (4)

Unknown

The Beaston West of Scotland Cancer Center, NHS Greater Glasgow and Clyde, Glasgow

Hammersmith Hospital, Imperial College Healthcare NHS Trust, London

Weston Park Hospital, Sheffield Teaching Hospitals, NHS Trust, Sheffield

M20 4BX

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors

collaborator

University of Leeds

OTHER

collaborator

Servier

INDUSTRY

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

The Christie NHS Foundation Trust

OTHER

NCT03837977 - Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma | Biotech Hunter | Biotech Hunter